Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 264

1.

Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for hodgkin and non-hodgkin lymphoma.

Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):175-82. doi: 10.1016/j.ijrobp.2015.02.010.

2.

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18)fluorodeoxyglucose positron emission tomography.

Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):113-21. doi: 10.1016/j.ijrobp.2015.02.006.

3.

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.

Oki Y, Younes A, Knicerkbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J.

Haematologica. 2015 Mar 27. pii: haematol.2015.126557. [Epub ahead of print] No abstract available.

4.

Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.

Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):122-9. doi: 10.1016/j.ijrobp.2015.01.014. Epub 2015 Mar 5.

PMID:
25754633
5.

Multimodality imaging of Epstein-Barr virus-associated inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen: case report and literature review.

Bui PL, Vicens RA, Westin JR, Jensen CT.

Clin Imaging. 2015 May-Jun;39(3):525-8. doi: 10.1016/j.clinimag.2014.12.021. Epub 2015 Jan 7.

PMID:
25725946
6.

A clinician's guide to double hit lymphomas.

Cheah CY, Oki Y, Westin JR, Turturro F.

Br J Haematol. 2015 Mar;168(6):784-95. doi: 10.1111/bjh.13276. Epub 2014 Dec 22. Review.

PMID:
25529575
7.

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS.

Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.

PMID:
25439689
8.

A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine.

Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver N, Borthakur G.

Front Oncol. 2014 Oct 29;4:297. doi: 10.3389/fonc.2014.00297. eCollection 2014.

9.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.

Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.

PMID:
25042202
10.

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A.

Br J Haematol. 2014 Oct;167(2):177-84. doi: 10.1111/bjh.13014. Epub 2014 Jul 8.

PMID:
25039868
11.

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR.

Br J Haematol. 2014 Sep;166(6):891-901. doi: 10.1111/bjh.12982. Epub 2014 Jun 18.

PMID:
24943107
12.

Evaluation of anamnestic criteria for the identification of patients with acute community onset viral gastroenteritis in the emergency department--A prospective observational study.

Andreasson T, Gustavsson L, Lindh M, Bergbrant IM, Raner C, Ahrén C, Westin J, Andersson LM.

Scand J Infect Dis. 2014 Aug;46(8):561-5. doi: 10.3109/00365548.2014.914242. Epub 2014 May 16.

PMID:
24832849
13.

Norovirus GII.4 detection in environmental samples from patient rooms during nosocomial outbreaks.

Nenonen NP, Hannoun C, Svensson L, Torén K, Andersson LM, Westin J, Bergström T.

J Clin Microbiol. 2014 Jul;52(7):2352-8. doi: 10.1128/JCM.00266-14. Epub 2014 Apr 23.

14.

A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis.

Ydreborg M, Lisovskaja V, Lagging M, Brehm Christensen P, Langeland N, Buhl MR, Pedersen C, Mørch K, Wejstål R, Norkrans G, Lindh M, Färkkilä M, Westin J.

PLoS One. 2014 Apr 3;9(4):e93601. doi: 10.1371/journal.pone.0093601. eCollection 2014.

15.

Busting robustness: using cancer's greatest strength to our advantage.

Westin JR.

Future Oncol. 2015 Jan;11(1):73-7. doi: 10.2217/fon.14.49.

PMID:
24673642
16.

Bone mineral density screening should be routine in lymphoma patients.

Thompson MA, Westin JR, Hagemeister FB.

Ann Oncol. 2014 Apr;25(4):913-4. doi: 10.1093/annonc/mdu044. No abstract available.

17.

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Westin JR.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):335-42. doi: 10.1016/j.clml.2014.01.007. Epub 2014 Feb 7.

PMID:
24650973
18.

Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy.

Jerkeman A, Norkrans G, Lidman C, Westin J, Lagging M, Frimand J, Simonsberg C, Kakko J, Widell A, Björkman P.

Eur J Gastroenterol Hepatol. 2014 May;26(5):523-31. doi: 10.1097/MEG.0000000000000076.

PMID:
24637496
19.

Reply: To PMID 24519039.

Lagging M, Rembeck K, Waldenström J, Nilsson S, Nyström K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, Färkkilä M, Langeland N, Buhl MR, Mørch K, Christensen PB, Hellstrand K.

Hepatology. 2014 Dec;60(6):2130-1. doi: 10.1002/hep.27108. Epub 2014 Sep 24. No abstract available.

PMID:
24591101
20.

Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy--factors associated with advanced fibrosis.

Jerkeman A, Westin J, Lagging M, Norkrans G, Lidman C, Frimand J, Simonsberg C, Kakko J, Widell A, Björkman P.

Scand J Infect Dis. 2014 May;46(5):340-7. doi: 10.3109/00365548.2013.879994. Epub 2014 Feb 20.

PMID:
24552582
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk